Nearwater Capital Markets Ltd bought a new stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 280,000 shares of the biopharmaceutical company's stock, valued at approximately $15,837,000.
Several other hedge funds also recently modified their holdings of the business. Aprio Wealth Management LLC raised its holdings in Bristol-Myers Squibb by 72.9% during the 4th quarter. Aprio Wealth Management LLC now owns 8,282 shares of the biopharmaceutical company's stock worth $468,000 after buying an additional 3,493 shares during the period. Fiduciary Alliance LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at $253,000. Brookstone Capital Management grew its stake in shares of Bristol-Myers Squibb by 11.0% in the fourth quarter. Brookstone Capital Management now owns 186,155 shares of the biopharmaceutical company's stock valued at $10,529,000 after buying an additional 18,516 shares in the last quarter. Wedmont Private Capital boosted its position in Bristol-Myers Squibb by 29.5% during the fourth quarter. Wedmont Private Capital now owns 10,487 shares of the biopharmaceutical company's stock worth $586,000 after purchasing an additional 2,392 shares during the period. Finally, Cooper Financial Group boosted its position in Bristol-Myers Squibb by 2.0% during the fourth quarter. Cooper Financial Group now owns 14,152 shares of the biopharmaceutical company's stock worth $800,000 after purchasing an additional 279 shares during the period. Institutional investors own 76.41% of the company's stock.
Insiders Place Their Bets
In other news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction dated Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president now directly owns 83,513 shares of the company's stock, valued at $3,973,548.54. This represents a 5.36% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.09% of the company's stock.
Bristol-Myers Squibb Price Performance
NYSE BMY traded up $0.96 during trading on Friday, hitting $46.77. 12,103,063 shares of the company's stock were exchanged, compared to its average volume of 13,242,297. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The company has a market cap of $95.18 billion, a PE ratio of -10.58, a P/E/G ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The stock's 50 day moving average price is $53.05 and its two-hundred day moving average price is $55.97.
Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business's quarterly revenue was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($4.40) earnings per share. Research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current year.
Bristol-Myers Squibb Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.30%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb's payout ratio is 92.88%.
Wall Street Analysts Forecast Growth
A number of research firms have commented on BMY. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Jefferies Financial Group reduced their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Finally, Piper Sandler began coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price for the company. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $58.00.
Get Our Latest Stock Report on Bristol-Myers Squibb
Bristol-Myers Squibb Company Profile
(
Free Report)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Further Reading
Before you consider Bristol-Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.
While Bristol-Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
